-
Mashup Score: 0
Benmelstobart plus anlotinib improved PFS, OS, and ORR vs sunitinib in first-line advanced renal cell carcinoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2
Benmelstobart plus anlotinib improved PFS, OS, and ORR vs sunitinib in first-line advanced renal cell carcinoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
Benmelstobart Plus Anlotinib Demonstrates Efficacy in Frontline Advanced RCC @myESMO #ESMO24 #oncology #MedTwitter #rcc https://t.co/gHp9aGAzSS